| Group . | Criterion . |
|---|---|
| 1 | Biomarker with approved biomarker specific treatment in glioblastoma + with strong survival benefit – with moderate survival benefit or inconsistent |
| 2A | Biomarker with approved biomarker specific treatment in another cancer indication with compelling clinical evidence in glioblastoma |
| 2B | Biomarker with approved biomarker specific treatment in another cancer indication not tested in glioblastoma in a clinical setting |
| 3A | Clinical evidence in glioblastoma, but not approved in glioblastoma or any other cancer indication + mutation – amp/expression |
| 3B | Clinical evidence in another cancer indication, makes biological sense in glioblastoma, but no clinical evidence in glioblastoma + mutation – amp/expression |
| 4A | No compelling clinical evidence in any cancer indication but retrospective biomarker assessment in + glioblastoma – another cancer indication |
| 4B | No compelling clinical evidence in any cancer indication, but stable genetic change (mutation/fusion) and makes biological sense in glioblastoma ± preclinical evidence |
| 4C | No compelling clinical evidence in any cancer indication, expression change, phosphorylation, etc. is a direct drug target and makes biological sense in glioblastoma |
| 4D | Alteration of pathways or genetic alteration/expression change regulates drug target |
| Group . | Criterion . |
|---|---|
| 1 | Biomarker with approved biomarker specific treatment in glioblastoma + with strong survival benefit – with moderate survival benefit or inconsistent |
| 2A | Biomarker with approved biomarker specific treatment in another cancer indication with compelling clinical evidence in glioblastoma |
| 2B | Biomarker with approved biomarker specific treatment in another cancer indication not tested in glioblastoma in a clinical setting |
| 3A | Clinical evidence in glioblastoma, but not approved in glioblastoma or any other cancer indication + mutation – amp/expression |
| 3B | Clinical evidence in another cancer indication, makes biological sense in glioblastoma, but no clinical evidence in glioblastoma + mutation – amp/expression |
| 4A | No compelling clinical evidence in any cancer indication but retrospective biomarker assessment in + glioblastoma – another cancer indication |
| 4B | No compelling clinical evidence in any cancer indication, but stable genetic change (mutation/fusion) and makes biological sense in glioblastoma ± preclinical evidence |
| 4C | No compelling clinical evidence in any cancer indication, expression change, phosphorylation, etc. is a direct drug target and makes biological sense in glioblastoma |
| 4D | Alteration of pathways or genetic alteration/expression change regulates drug target |
| Group . | Criterion . |
|---|---|
| 1 | Biomarker with approved biomarker specific treatment in glioblastoma + with strong survival benefit – with moderate survival benefit or inconsistent |
| 2A | Biomarker with approved biomarker specific treatment in another cancer indication with compelling clinical evidence in glioblastoma |
| 2B | Biomarker with approved biomarker specific treatment in another cancer indication not tested in glioblastoma in a clinical setting |
| 3A | Clinical evidence in glioblastoma, but not approved in glioblastoma or any other cancer indication + mutation – amp/expression |
| 3B | Clinical evidence in another cancer indication, makes biological sense in glioblastoma, but no clinical evidence in glioblastoma + mutation – amp/expression |
| 4A | No compelling clinical evidence in any cancer indication but retrospective biomarker assessment in + glioblastoma – another cancer indication |
| 4B | No compelling clinical evidence in any cancer indication, but stable genetic change (mutation/fusion) and makes biological sense in glioblastoma ± preclinical evidence |
| 4C | No compelling clinical evidence in any cancer indication, expression change, phosphorylation, etc. is a direct drug target and makes biological sense in glioblastoma |
| 4D | Alteration of pathways or genetic alteration/expression change regulates drug target |
| Group . | Criterion . |
|---|---|
| 1 | Biomarker with approved biomarker specific treatment in glioblastoma + with strong survival benefit – with moderate survival benefit or inconsistent |
| 2A | Biomarker with approved biomarker specific treatment in another cancer indication with compelling clinical evidence in glioblastoma |
| 2B | Biomarker with approved biomarker specific treatment in another cancer indication not tested in glioblastoma in a clinical setting |
| 3A | Clinical evidence in glioblastoma, but not approved in glioblastoma or any other cancer indication + mutation – amp/expression |
| 3B | Clinical evidence in another cancer indication, makes biological sense in glioblastoma, but no clinical evidence in glioblastoma + mutation – amp/expression |
| 4A | No compelling clinical evidence in any cancer indication but retrospective biomarker assessment in + glioblastoma – another cancer indication |
| 4B | No compelling clinical evidence in any cancer indication, but stable genetic change (mutation/fusion) and makes biological sense in glioblastoma ± preclinical evidence |
| 4C | No compelling clinical evidence in any cancer indication, expression change, phosphorylation, etc. is a direct drug target and makes biological sense in glioblastoma |
| 4D | Alteration of pathways or genetic alteration/expression change regulates drug target |
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
